DOI: 10.1002/alr.70248 ISSN: 2042-6976
Bevacizumab Reduces Epistaxis‐Related Operative Burden in Hereditary Hemorrhagic Telangiectasia
Nathan Barefoot, Priya J. Desai, Anna van Dorsten, Elena Quinonez Del Cid, Katrina Bootes, Ismail Khaderi, Ezer H. Benaim, Jackson Vuncannon, Cristine Klatt‐Cromwell, Charles S. Ebert, Raj S. Kasthuri, Brent A. Senior, Brian D. Thorp, Adam J. KimpleKey Points
Bevacizumab reduced epistaxis‐related ablation frequency by 55.6% in HHT patients. Over half of HHT patients (57.7%) required no ablation intervention after bevacizumab initiation. Maintenance bevacizumab dosing remains highly variable, underscoring the need for standardization.